Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.

CONCLUSION: These results suggest that PS and platelet count are independent prognostic factors and that a combination of these factors can be used to stratify metastatic prostate cancer patients treated with endocrine therapy according to their DSS risk. PMID: 30882158 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30882158?dopt=Abstract

Source: Urology Journal - March 17, 2019 Category: Urology & Nephrology Authors: Shimodaira K, Nakashima J, Nakagami Y, Hirasawa Y, Hashimoto T, Satake N, Gondo T, Namiki K, Ohori M, Ohno Y Tags: Urol J Source Type: research